Satavaptan
From Self-sufficiency
| 280px | |
| Systematic (IUPAC) name | |
|---|---|
|
N-(tert-butyl)-4-{[(1s,4s)-5'-ethoxy-4-(2-morpholin-4-ylethoxy)-2'-oxospiro[cyclohexane-1,3'-indol]-1'(2'H)-yl]sulfonyl}-3-methoxybenzamide | |
| Identifiers | |
| CAS Number | 185913-78-4 |
| ATC code | none |
| PubChem | CID 9810773 |
| Chemical data | |
| Formula | C33H45N3O8S |
| Molar mass | 643.789[[Script error: No such module "String".]] |
Satavaptan (INN; codenamed SR121463, planned tradename Aquilda) is a vasopressin-2 receptor antagonist[1] undergoing research for the treatment of hyponatremia. It is also being studied for the treatment of ascites.[2]
It was developed by Sanofi-Aventis. As of 2008, it is under regulatory review in the European Union.
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 30px | This drug article relating to the cardiovascular system is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
- Diuretics
- Hormonal agents
- Cardiovascular system drug stubs
